Navigation Links
NOVAVAX Announces Positive Preclinical Results for its Respiratory Syncytial Virus (RSV) Vaccine Candidate
Date:1/12/2010

ROCKVILLE, Md., Jan. 12 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats.  Results from this study are needed to support an Investigational New Drug (IND) application to advance this novel recombinant F protein particle based RSV (RSV-F) vaccine candidate into clinical development.  This vaccine candidate is composed of recombinant 'F' or 'fusion' protein of RSV which is used by the virus to infect and fuse with cells in the respiratory tract and cause disease.  

In the current study, Novavax tested its RSV-F vaccine candidate in cotton rats, a well accepted animal model for RSV infection and disease.  The animals received two injections on days one and 21 with 1, 6 or 30 micrograms of RSV-F vaccine with or without an alum adjuvant.  All dose groups produced antibodies that neutralize RSV, and with adjuvant, only a single injection of RSV-F was needed to induce high levels of neutralizing antibodies.  The immunized cotton rats were challenged with live RSV to test if they were protected from infection.  High levels of virus were measured in unimmunized control animals but no RSV was detected in the lungs of animals immunized with any dose of the Novavax RSV-F vaccine, with or without adjuvant.  

RSV vaccines require a heightened evaluation of safety because of a failed study in children in the mid-1960s with a formalin-inactivated RSV vaccine candidate that caused enhancement of the disease.  In the current study, the lungs of RSV challenged cotton rats were examined and there was no sign that immunization with the Novavax RSV-F vaccine candidate resulted in enhance
'/>"/>

SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , September 30, 2014 ... intuitive browsing of chemistry in documents ... software solutions and consulting services for life science ... information and generate Markush structures from documents. ... organizations intellectual property, however generating and understanding Markush ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 OriginOil Inc. ... high-speed, chemical-free process to clean up large quantities of ... CEO Riggs Eckelberry reported on the launch of the ... a site provided by partner STW Resources . ... 1000 barrels per day (bpd) and achieved a 99.8% ...
(Date:9/30/2014)... BALTIMORE and ROCKVILLE, Md., Sept. 30, 2014 /PRNewswire/ ... private-public partnership focusing on commercializing market-relevant biohealth innovations and ... Maryland , announced today that venture capitalist, ... as a strategic advisor. Dr. Fernandez will be a ... Gap Fund, which will provide up to $50 million ...
(Date:9/30/2014)... iLab Solutions announced the results of its ... on core facility operations, growth and utilization as well ... In its 4th year running, a number of long-term ... decrease in the percentage of revenue that comes from ... constraints of this trend. When asked, “What are your ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3
... Kansas to its annual promotional campaign of biotechnological, pharmaceutical and medical device companies ... , , (Logo:   ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... July 29 Omeros Corporation (Nasdaq: OMER ) ... facility under which it may sell up to $40 ... Opportunity, Ltd. (the "investor") over a 24-month period. Omeros is ... enter into and consummate other equity, debt and non-dilutive financing ...
... ,, LONDON , ... pleased,to announce the appointment of Dr Neill Moray Mackenzie ... to CMPT a long record of executive,board level management ... Genetics Ltd, Oxford Biomedica plc (an LSE,listed company), Avidex ...
Cached Biology Technology:BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 2CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 5
(Date:9/30/2014)... Munich report that a new class of chemical ... drugs. They have also pinpointed the relevant target ... agents. , Researchers led by LMU,s Professor ... Technische Universitt Mnchen have identified a class of ... the fight against malignant tumors. The compound is ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for the American Association of Immunologists 2013 ... from July 13-18, 2013. These awards are meant ... scientists from underrepresented groups into the mainstream of ...
... progress in the search for the first broad-spectrum drugs ... common infectious diseases. Their study on these potential drugs ... the journal ACS Medicinal Chemistry Letters . ... HRV infections cause mild disease, they can lead to ...
... teachers to sing melodies accurately, according to a new ... the University of Kaiserslautern in Germany. Their analysis of ... songbirds, brain processes. The work is published online in ... is considered to be one of the most complex ...
Cached Biology News:Songbirds turn on and tune up 2
Recombinant Feline IFN-alpha...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Biology Products: